The EU funded project TTV GUIDE TX has kicked-off and looks to establish a tool to quantify the activity of the immune system in kidney transplant patients and thereby reducing infections and organ rejections. The final goal of the project is to improve the life of kidney transplant patients.
Transplant physicians need a tool to quantify the activity of the immune system and optimize the drug dose. The recently discovered Torque Teno virus (TTV) might do the job. Within the TTV GUIDE TX project, TT virus guided dosing of immunosuppressive drugs will be tested in a clinical trial including hundreds of kidney transplant recipients from all over Europe.
ECRIN is a partner in the TTV GUIDE TX project, where TT virus guided dosing of immunosuppressive drugs will be tested in a clinical trial including hundreds of kidney transplant recipients from all over Europe. In the future, the TT virus might not only help kidney transplant recipients but also patients with liver, heart and lung transplants and guide therapy in autoimmune, infectious and oncologic diseases.
TTV GUIDE TX is coordinated by the Medical University of Vienna (Austria), and brings together 19 partners, including kidney transplant physicians, clinical virologists, project and clinical trial managers, ethicists and health care industry professionals, from 7 EU countries to run a clinical trial with almost 300 patients. The TTV GUIDE TX project will work closely with The European Kidney Patients’ Federation (EKPF), the European umbrella organisation for 23 national kidney patients’ associations.
The project officially started on 1st May 2021, for a duration of 60 months. It has received support from the European Union Framework Programme for Research and Innovation Horizon 2020 (GA 896932) with a total budget of €6 Million.